Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM11260C in type 2 diabetes mellitus
NCT01452451Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2011
- Primary completion
- Jun 2013
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efpeglenatide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Number of subjects with adverse events as a measure of safety and tolerability at 106 days. Started Dec 2011; status: completed.
02
Drugs
efpeglenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01452451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01452451.